Long-circulating liposome modified with c(RGD-ACP-K)
US11260068B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 24, 2018 |
| Grant date | Mar 1, 2022 |
| Priority date | — |
| Expiry date | May 24, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a long-circulating liposome modified with c(RGD-ACP-K). The present invention pertains to the field of pharmaceutical preparations, in particular to the field of targeted pharmaceutical preparations. More specifically, the present invention relates to a long-circulating liposome, the surface of the liposome being modified with c(RGD-ACP-K), and the liposome comprising doxorubicin or a pharmaceutically acceptable salt thereof such as doxorubicin hydrochloride as an anti-cancer active agent. The long-circulating liposome can targetedly deliver the anti-cancer active agent into tumor neovascular endothelial cells and tumor cells and can prolong the circulation time of the liposome in vivo, thereby enhancing the therapeutic effect of anti-tumor medicaments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.